BioNTech’s Tumultuous Journey: From Pandemic Triumph to Cancer-Curing Pioneer
BioNTech is transitioning from mRNA COVID-19 vaccines to pioneering cancer therapies. Recent financial reports show decreased profits, with earnings per share at 1.08 euros but exceeding expectations of 0.407 euros.…